MercÃ" Brunet Serra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5819801/publications.pdf

Version: 2024-02-01

49 papers

2,742 citations

279701 23 h-index 206029 48 g-index

50 all docs

50 docs citations

50 times ranked

3567 citing authors

#	Article	lF	CITATIONS
1	Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. Journal of Hepatology, 2007, 46, 474-481.	1.8	864
2	Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference. Therapeutic Drug Monitoring, 2009, 31, 139-152.	1.0	398
3	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplantation Reviews, 2011, 25, 47-57.	1.2	116
4	Therapeutic Drug Monitoring of Everolimus. Therapeutic Drug Monitoring, 2016, 38, 143-169.	1.0	102
5	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice. Therapeutic Drug Monitoring, 2016, 38, 170-189.	1.0	95
6	The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrology Dialysis Transplantation, 2009, 24, 2269-2276.	0.4	81
7	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. Therapeutic Drug Monitoring, 2016, 38, S1-S20.	1.0	78
8	Effect of Mycophenolate Mofetil on Immune Response and Plasma and Lymphatic Tissue Viral Load During and After Interruption of Highly Active Antiretroviral Therapy for Patients With Chronic HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 823-830.	0.9	71
9	Efficacy and Safety of Fosfomycin Plus Imipenem as Rescue Therapy for Complicated Bacteremia and Endocarditis Due to Methicillin-Resistant Staphylococcus aureus: A Multicenter Clinical Trial. Clinical Infectious Diseases, 2014, 59, 1105-1112.	2.9	67
10	Sequential Determination of Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid in Liver Transplant Patients Treated with Mycophenolate Mofetil. Transplantation, 2006, 81, 541-546.	0.5	55
11	Risk Factors for a Low Linezolid Trough Plasma Concentration in Acute Infections. Antimicrobial Agents and Chemotherapy, 2013, 57, 1913-1917.	1.4	53
12	Mammalian Target of Rapamycin Inhibition Halts the Progression of Proteinuria in a Rat Model of Reduced Renal Mass. Journal of the American Society of Nephrology: JASN, 2007, 18, 2653-2660.	3.0	52
13	Pharmacodynamic Approach to Immunosuppressive Therapies Using Calcineurin Inhibitors and Mycophenolate Mofetil. Clinical Chemistry, 2003, 49, 1891-1899.	1.5	49
14	Proteomic analysis of the secretome of human umbilical vein endothelial cells using a combination of freeâ€flow electrophoresis and nanoflow LCâ€MS/MS. Proteomics, 2009, 9, 4991-4996.	1.3	44
15	Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy. Clinical Immunology, 2010, 137, 337-346.	1.4	43
16	Interaction Between Everolimus and Tacrolimus in Renal Transplant Recipients: A Pharmacokinetic Controlled Trial. Transplantation, 2010, 89, 994-1000.	0.5	42
17	Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections. Scandinavian Journal of Infectious Diseases, 2012, 44, 548-550.	1.5	38
18	Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. Kidney International, 2014, 85, 1434-1443.	2.6	38

#	Article	IF	CITATIONS
19	Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study. Nephrology Dialysis Transplantation, 2011, 26, 3784-3793.	0.4	37
20	High Proportion of Pretransplantation Activated Regulatory T cells (CD4+CD25highCD62L+CD45RO+) Predicts Acute Rejection in Kidney Transplantation. Transplantation, 2014, 98, 1213-1218.	0.5	35
21	Is the Intracellular ATP Concentration of CD4+ T-Cells a Predictive Biomarker of Immune Status in Stable Transplant Recipients?. Transplantation, 2009, 88, S78-S84.	0.5	31
22	Low-Dose Cyclosporine with Mycophenolate Mofetil Induces Similar Calcineurin Activity and Cytokine Inhibition as does Standard-Dose Cyclosporine in Stable Renal Allografts. Transplantation, 2004, 78, 1400-1403.	0.5	30
23	Determination of atorvastatin and its metabolite ortho-hydroxyatorvastatin in human plasma by on-line anion-exchange solid-phase extraction and liquid chromatography tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2009, 394, 1687-1696.	1.9	25
24	Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients. Journal of Clinical Pharmacology, 2013, 53, 1146-1154.	1.0	23
25	Effects of Cyclosporine, Tacrolimus and Sirolimus on Vascular Changes Related to Immune Response. Journal of Heart and Lung Transplantation, 2008, 27, 416-422.	0.3	21
26	Development and validation of a UHPLC diode array detector method for meropenem quantification in human plasma. Clinical Biochemistry, 2014, 47, 223-227.	0.8	21
27	Monitoring of miR-181a-5p and miR-155-5p Plasmatic Expression as Prognostic Biomarkers for Acute and Subclinical Rejection in de novo Adult Liver Transplant Recipients. Frontiers in Immunology, 2019, 10, 873.	2.2	21
28	High frequency of central memory regulatory T cells allows detection of liver recipients at risk of early acute rejection within the first month after transplantation. International Immunology, 2016, 28, 55-64.	1.8	19
29	Pharmacokinetics and Pharmacodynamics of Low Dose Mycophenolate Mofetil in HIV-Infected Patients Treated with Abacavir, Efavirenz and Nelfinavir. Clinical Pharmacokinetics, 2005, 44, 525-538.	1.6	16
30	Effects of Longâ€Term Antiepileptic Therapy on the Catabolism of Testosterone. Basic and Clinical Pharmacology and Toxicology, 1995, 76, 371-375.	0.0	15
31	Improved Renal Function, With Similar Proteinuria, After Two Years of Early Tacrolimus Withdrawal From a Regimen of Sirolimus Plus Tacrolimus. Transplantation, 2008, 86, 620-622.	0.5	15
32	Biomarkers of the immunomodulatory effect of immunosuppressive drugs in transplant recipients. Transplantation Reviews, 2009, 23, 120-128.	1.2	15
33	Pharmacokinetic Study of Saquinavir 500 mg Plus Ritonavir (1000/100 mg Twice a Day) in HIV-Positive Pregnant Women. Therapeutic Drug Monitoring, 2011, 33, 772-777.	1.0	15
34	T-Cell Cytokines as Predictive Markers of the Risk of Allograft Rejection. Therapeutic Drug Monitoring, 2016, 38, S21-S28.	1.0	14
35	Positive versus negative symptoms in schizophrenia: Response to haloperidol. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1994, 18, 155-164.	2.5	13
36	Monitoring of Donorâ€Derived Cellâ€Free DNA by Short Tandem Repeats: Concentration of Total Cellâ€Free DNA and Fragment Size for Acute Rejection Risk Assessment in Liver Transplantation. Liver Transplantation, 2022, 28, 257-268.	1.3	13

#	Article	IF	CITATIONS
37	High proportion of CD95+ and CD38+ in cultured CD8+ T cells predicts acute rejection and infection, respectively, in kidney recipients. Transplant Immunology, 2016, 34, 33-41.	0.6	12
38	High expression of CD38, CD69, CD95 and CD154 biomarkers in cultured peripheral T lymphocytes correlates with an increased risk of acute rejection in liver allograft recipients. Immunobiology, 2016, 221, 595-603.	0.8	12
39	Therapeutic Drug Monitoring of Tacrolimus in Liver Transplantation, Phase III FK506 Multicenter Spanish Study Group: A Two-Year Follow-Up. Therapeutic Drug Monitoring, 1998, 20, 602-606.	1.0	10
40	Multicenter Comparison of First- and Second-Generation IMx Tacrolimus Microparticle Enzyme Immunoassays in Liver and Kidney Transplantation. Therapeutic Drug Monitoring, 1998, 20, 676-679.	1.0	10
41	Antimicrobial and immunosuppressive drug interactions in solid organ transplant recipients. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2012, 30, 86-92.	0.3	9
42	Voriconazole and cobicistat-boosted antiretroviral salvage regimen co-administration to treat invasive aspergillosis in an HIV-infected patient. Journal of Antimicrobial Chemotherapy, 2016, 71, 1125-1127.	1.3	7
43	Pharmacokinetic Study of Dual Therapy With Raltegravir 400 mg Twice Daily and Darunavir/Ritonavir 800/100 mg Once Daily in HIV-1–Infected Patients. Therapeutic Drug Monitoring, 2013, 35, 552-556.	1.0	4
44	Pharmacodynamics of T cell function for monitoring pharmacologic immunosuppression after allogeneic hematopoietic stem cell transplantation. International Journal of Hematology, 2017, 105, 497-505.	0.7	4
45	Individually Tailored Immunosuppression: Is There a Role for Biomarkers?. Clinical Chemistry, 2011, 57, 376-381.	1.5	3
46	Donor–recipient genetic diversity: the role of†pharmacogenomics in kidney transplantation. Pharmacogenomics, 2013, 14, 1369-1372.	0.6	3
47	Flow Cytometry as Platform for Biomarker Discovery and Clinical Validation. Biomarkers in Disease, 2015, , 141-164.	0.0	1
48	Determinación de linezolid en plasma mediante cromatografÃa lÃquida de alta resolución para la monitorización terapéutica en pacientes. Revista Del Laboratorio ClÃnico, 2011, 4, 207-213.	0.1	0
49	EvaluaciÃ ³ n de las concentraciones plasmáticas de voriconazol en práctica clÃnica. Ars Pharmaceutica, 2021, 62, 305-314.	0.1	0